# Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence

> **NCT05062096** · NA · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 220 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** Blood samples
- **OTHER:** Skin biopsy

## Key facts

- **NCT ID:** NCT05062096
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-02
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2022-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05062096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05062096, "Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05062096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*